-
公开(公告)号：US20190240199A1
公开(公告)日：2019-08-08
申请号：US16318468
申请日：2017-07-20
Inventor： Iris LAVON BEN MOSHE , Tamar CANELLO AVRAMOVITCH
IPC: A61K31/4166 , A61P35/00 , A61K31/517 , A61K31/175 , G01N33/50 , G01N33/574
CPC classification number: A61K31/4166 , A61K31/175 , A61K31/517 , A61K45/06 , A61P35/00 , G01N33/5011 , G01N33/57407 , G01N2800/52 , A61K2300/00
Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
-
22.发明申请公开(公告)号：US20190209274A1
公开(公告)日：2019-07-11
申请号：US16217250
申请日：2018-12-12
Inventor： Uri BARAK , Eyal TARAZI
IPC: A61C13/107 , A61C9/00 , A61C13/00 , A61C5/77 , A61C1/00 , A61C1/08 , A61C5/00 , A61C5/90 , A61B34/30 , A61B34/20
CPC classification number: A61C13/0001 , A61B34/20 , A61B34/30 , A61C1/0015 , A61C1/0046 , A61C1/082 , A61C1/084 , A61C5/007 , A61C5/77 , A61C5/80 , A61C5/82 , A61C5/90 , A61C9/0053 , A61C13/0004
Abstract: A system and method of automated formation of a preparation stub, based on an a priori created computational geometrical model, configured to conform to a prefabricated fixed dental prosthesis, is described. The system includes a digital imaging facility with an image acquiring device and a three-dimensional data digitizer, a modeling facility with an exterior surface design module and an interior surface design module, a fabrication facility operatively with a computer-aided manufacturing module, as well as an application facility including an ablation tool and in-situ preparation module; application facility preferably includes an intra-oral feedbacking appliance with a distance measurement probe for automated feedback-controlled formation of a preparation stub.
-
公开(公告)号：US10292598B2
公开(公告)日：2019-05-21
申请号：US14569396
申请日：2014-12-12
Inventor： Dean Nahman , Yaron Ilan , Ilan Ben Oren , Yaron Bar-Ilan , Shmuel Chen
Abstract: A device for detection of internal bleeding in a patient's body is provided. An optical interface for transmitting IR light through an area of a skin of a patient and to collect IR light from the area of the skin, is provided. In some embodiments the optical interface includes one or more delivery components and one or more collection components. The delivery component includes a plurality of first optical channels configured to transmit the IR light through a plurality of respective first sub-areas on the area of the skin, into an internal layer of the body. The collection component includes a plurality of second optical channels, configured to collect IR light from a plurality of respective second sub-areas on the area of the skin.
-
公开(公告)号：US20180215709A1
公开(公告)日：2018-08-02
申请号：US15126023
申请日：2015-03-16
Inventor： Bernard LERER , Mugesh GOVINDASAMY , Tzuri LIFSCHYTZ
IPC: C07D207/456 , A61P25/24 , A61P35/00 , C07D405/06
CPC classification number: C07D207/456 , A61K31/4015 , A61K31/402 , A61K31/4025 , A61P25/24 , A61P35/00 , C07D405/06 , C07D517/04
Abstract: The present invention relates to compounds that inhibit the activity of Type III deiodinase (DIO3). The present invention further relates to methods for treating or preventing depression, depression associated with other psychiatric or general medical diseases or conditions, condition amenable to treatment with known anti-depressants and cancer, particularly by using the compounds of the invention.
-
公开(公告)号：US20170121767A1
公开(公告)日：2017-05-04
申请号：US15303762
申请日：2015-04-14
Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. , Hadasit Medical Research Services and Development Ltd.
Inventor： Yuval DOR , Ruth SHEMER , Benjamin GLASER
IPC: C12Q1/68
CPC classification number: C12Q1/6881 , C12Q1/6883 , C12Q1/6886 , C12Q2600/154
Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US20160333072A1
公开(公告)日：2016-11-17
申请号：US15110111
申请日：2015-01-08
Inventor： Abraham RUTENBERG , Ronny UZANA , Michal LOTEM , Arthur MACHLENKIN , Galit EISENBERG , Tamar PERETZ-YABLONSKY , Shoshana FRANKENBURG , Roni ENGELSTEIN
IPC: C07K14/705 , A61K39/395 , C12N5/0783 , A61K39/39 , A61K35/17 , C07K16/28 , A61K45/06
CPC classification number: C07K14/70503 , A61K35/17 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/75 , C12N5/0638 , C12N2501/998
Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
Abstract translation: 仅针对免疫治疗领域。 具体地，提供了用于体外和体内改善T细胞调节以及用于治疗癌症和其它病症的组合物和方法。 更具体地，本发明的实施方案涉及可溶性NTB-A多肽或其激动剂在治疗癌症患者中的用途，用于预防和治疗易感患者中的血细胞减少，以及用于离体制备改善的细胞组合物。
-
27.发明申请Compositions, methods and kits for diagnosis of carriers of mutations in the BRCA1 and BRCA2 genes and early diagnosis of cancerous disorders associated with mutations in BRCA1 and BRCA 2 genes 审中-公开用于诊断BRCA1和BRCA2基因突变载体的组合物，方法和试剂盒以及与BRCA1和BRCA2基因突变相关的癌性疾病的早期诊断公开(公告)号：US20150354014A1
公开(公告)日：2015-12-10
申请号：US14834989
申请日：2015-08-25
Inventor： Asher SALMON , Tamar PERETZ
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/156 , C12Q2600/158
Abstract: The present invention relates to diagnostic compositions methods and kits for the detection of carriers of mutations in the BRCA1 and BRCA2 genes. The detection is based on the use of detecting nucleic acids or amino acid based molecules, specific for determination of the expression of at least six marker genes of the invention, in a test sample. The invention thereby provides methods compositions and kits for the diagnosis of cancerous disorders associated with mutations in the BRCA1 and BRCA2 genes, specifically, of ovarian and breast cancer.
Abstract translation: 本发明涉及用于检测BRCA1和BRCA2基因突变载体的诊断组合物方法和试剂盒。 检测是基于在测试样品中使用检测核酸或基于氨基酸的分子，其特异性用于测定本发明的至少六个标记基因的表达。 因此，本发明提供了用于诊断与BRCA1和BRCA2基因，特别是卵巢癌和乳腺癌中的突变相关的癌性病症的方法组合物和试剂盒。
-
28.发明申请公开(公告)号：US20150125506A1
公开(公告)日：2015-05-07
申请号：US14583838
申请日：2014-12-29
Inventor： Masha IDELSON , Ruslana ALPER-PINUS , Alex OBOLENSKY , Eyal BANIN , Benjamin Eithan REUBINOFF
CPC classification number: A61K35/30 , A61K9/0051 , A61K35/44 , A61K35/48 , C12N5/0621 , C12N5/0696 , C12N2500/38 , C12N2500/90 , C12N2500/99 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/999 , C12N2502/13 , C12N2506/02 , C12N2533/52
Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
-
29.发明申请Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders 有权β-糖脂的组合疗法和抗体用于治疗免疫相关性疾病公开(公告)号：US20140255420A1
公开(公告)日：2014-09-11
申请号：US14183248
申请日：2014-02-18
Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventor： Yaron Ilan , Howard L. Weiner
IPC: A61K39/395 , A61K31/7028
CPC classification number: A61K39/3955 , A61K31/7028 , A61K31/7032 , A61K45/06 , C07K16/2809 , A61K2300/00
Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
Abstract translation: 本发明涉及用于治疗免疫相关疾病的组合疗法。 更具体地说，本发明涉及将β-糖脂，优选与β-糖蛋白 - 脂质与至少一种来自免疫系统组分的抗原，特别是抗CD3抗体特异的免疫球蛋白分子组合的口腔或粘膜协同组合物。 本发明还提供了本发明的组合组合物用于免疫调节并由此用于治疗免疫相关疾病的方法试剂盒和用途。 在优选的实施方案中，抗-CD3抗体（OKT3）与2型糖尿病动物模型中的β-葡糖基神经酰胺（也称为糖脑啡肽）组合口服施用。
-
公开(公告)号：US20140073765A1
公开(公告)日：2014-03-13
申请号：US14116796
申请日：2012-05-09
Applicant: Hadasit Medical Research Services and Development Ltd. , Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventor： Dan Deutsch , Amir Haze , Anat Blumenfeld
IPC: C07K14/78
CPC classification number: C07K14/78 , A61K35/28 , A61K38/39 , C12N5/0663 , C12N2510/00 , C12N2710/10041
Abstract: A method of treating an injury to or a disease of a skeletal joint ligament is disclosed. The method comprises contacting the skeletal joint ligament or tendon of the subject with a therapeutically effective amount of amelogenin, wherein the amelogenin is not comprised in a scaffold, thereby treating the injury to or disease of the skeletal joint ligament or tendon.
Abstract translation: 公开了一种治疗骨骼关节韧带损伤或疾病的方法。 该方法包括使受试者的骨骼关节韧带或肌腱与治疗有效量的牙釉蛋白接触，其中所述e原蛋白不包含在支架中，从而治疗骨骼关节韧带或腱的损伤或疾病。
-
-
-
-
-
-
-
-
-
Search Results
180
records
(took 0.042 seconds)
